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tubular acidosis and nephrocalcinosis from early
childhood, without evidence of other tubular ab-
normalities except inability to concentrate the urine.
Her defect was almost certainly restricted to the distal
and collecting tubules although we did not measure
her bicarbonate threshold to confirm that it was normal.
Inability to concentrate the urine is a usual finding
by the time renal tubular acidosis is diagnosed.
Occasionally the disease is diagnosed before the onset
of a concentration defect,5 as in the youngest child
described here. This ability to concentrate confirms
that a concentration defect is not an integral part of
the inherited tubular abnormality. The concen-
tration defect is probably caused by nephrocalcinosis,
which in the early stages may not be visible on radio-
graphs. Judged from her plasma-bicarbonate con-
centration the eldest child was not acidotic, and be-
cause of her acidification defect might therefore be
considered to have an " incomplete " syndrome of
renal tubular acidosis 2; the fact that she did not
concentrate her urine well suggests that she already
has nephrocalcinosis, although it was not visible on
radiographs. Renal biopsy and arterial puncture in
these children were not justified.
Growth had been impaired only in the second child,
whose acidification defect was the most severe and
whose nephrocalcinosis was easily seen. Although we
found no evidence of rickets, her short stature sug-
gested that her bone growth had suffered to a degree
short of development of rickets while she buffered
retained hydrogen ion with bone salts.6-8 The natural
history of renal tubular acidosis is such that all three
children were liable to increasing acidosis and to its
complications such as nephrolithiasis, osteomalacia,
and potassium depletion. To prevent these compli-
cations all the children have been treated since 1967
with 65 meq. of sodium bicarbonate daily. They
rarely attend follow-up, but in 1969 we knew that the
second child was taking her treatment because her
plasma-bicarbonate was 24 mmole per litre. Her
nephrocalcinosis was unchanged.
This is the third family in which inheritance of
renal tubular acidosis as an autosomal mendelian
dominant seems thoroughly established, the others being
those described by Pitts, Randall, and colleagues 10-12
and by Gyory and Edwards. 13 In their review of
inheritance in this disease 14 Seldin and Wilson state
that, on the basis of ten families with evidence of trans-
mission through two or more generations, " it seems
reasonable to conclude that renal tubular acidosis may
occur as a mendelian dominant trait ". However,
most cases of renal tubular acidosis seem to be sporadic
in nature.
Requests for reprints should be addressed to P. R., Medical
Unit, St. Mary’s Hospital Medical School, London W.2.
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Summary 
Ten euthyroid women with unipolar
depression were treated with a single
injection of thyrotropin-releasing hormone (T.R.H.)
and a single injection of saline in a double-blind, cross-
over comparison. T.R.H. caused a prompt, brief
improvement in depression without causing significant
side-effects Most patients showed a reduced thyro-
tropin (T.S.H.) response to T.R.H. injection, though none
had abnormal thyroid function tests or clinical findings
suggesting pituitary or thyroid disease.
Introduction
THYROTROPIN-RELEASING hormone (T.R.H.), a sub-
stance of hypothalamic origin, is a potent and non-
toxic stimulator of pituitary thyrotropin (T.S.H.) 1,2 a
and pituitary prolactin 3,4 in man. Our interest in
T.R.H. (or any agent that would cause T.S.H. release)
stems from our work demonstrating that L-triiodothyro-
nine (T3) will potentiate the antidepressant effects
of tricyclic drugs in women.5-1I Further work by our
group indicated that T.S.H. also potentiates tricyclic
antidepressants, presumably by causing release of
thyroid hormones. 12, 13 s
These findings prompted us to examine the psycho-
pharmacological effects of T.R.H. in animals. With
N. P. Plotnikoff, we investigated the activity of T.R.H.
in the pargyline/L-dopa potentiation test, which has
been used to screen drugs for antidepressant potential. 14
T.R.H. was active in this test and, surprisingly, was
equally active in intact and hypophysectomised mice."
These data suggest that L-dopa potentiation by T.R.H.
in animals is not mediated via increased secretion
of T.S.H. or thyroid hormones and that an extra-
pituitary mechanism is at work. Although this study
did not clarify the mechanisms for our earlier findings,
A brief account of these findings was presented at the eighth
meeting of the Collegium Internationale Neuro-Psycho-
pharmacologicum, in Copenhagen on Aug. 14, 1972 (Psycho-
pharmacologia, 1972, 26, suppl. p. 82).
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it did suggest that T.R.H. might have antidepressant
activity. We present here our observations on eighteen
depressed women who were treated with intravenous
T.R.H.
To discern proper dose and possible toxicity, we
studied eight women with unipolar depression in a
flexible single-blind study. A single intravenous
injection of T.R.H., from 200 to 800 g., seemed
sufficient to cause prompt, brief, clinical improvement.
500-600 g. seemed more effective than smaller doses.
One woman received 800 g. Although generally
improved she complained that she felt " jittery "
for a few hours. Several patients experienced a sen-
sation of slight warmth shortly after injection. It
seemed possible largely to avoid this effect by using
a full minute to inject the hormone. No other side-
effects were noted, and there was no evidence of toxicity
due to T.R.H. Other data pertaining to these eight
patients have been excluded from the present report.
Patients and Methods
A double-blind cross-over study against placebo in-
jection was designed. Women between the ages of 25 and
45 admitted to the Dorothea Dix Hospital with primary 16
unipolar 17 depression were admitted to the study and trans-
ferred to the research unit if they gave informed consent,
if they did not use oral contraceptive preparations, if
they presented no physical, historical, or chemical evidence
of thyroid disorder, and if they were generally in good
physical health and were not pregnant. Most patients had
taken small amounts of various psychotropic drugs for
brief periods of time. We stopped these medications and
then gave thrice daily two capsules of placebo which matched
imipramine. If, after 7-10 days of placebo medication and
general care, the patient still scored substantially on the
Hamilton rating scale for depression (H.R.s.) (18), the patient
was assigned to group A (five patients) or group B (five
patients) according to a prearranged schedule balanced
for age. We did not distinguish between the various pos-
sible descriptive subtypes of unipolar depression because
such distinctions have not been useful in our previous
studies.
Group A patients were treated as follows. After base-
line assessments, the patient lay supine in bed. A con-
tinuous intravenous infusion was begun in one arm; a
blood-pressure cuff was attached to the other arm. At
9 A.M., 2 hours after breakfast, 600 jig. T.R.H. was slowly
injected into the intravenous tubing. At regular intervals
blood was withdrawn for later analyses of T.S.H. by specific
radioimmunoassay,19 thyroxine (T4) iodine,2O residual T4
binding space,21 and total serum-T3,22 baseline samples
having been obtained earlier. The nurse giving the in-
jections was in sole possession of the medication code.
Apart from the injections she had no immediate respon-
sibility to this group of patients. Another nurse, obtaining
blood-pressure and pulse recordings regularly, sat with
the patient and conversed or remained silent, according
to the patient’s wish. The patient was allowed out of bed at
noon.
A psychiatrist visited the patient at 8 A.M. and hourly
thereafter until 3 P.M., except at 1 P.M. At 3 P.M. he did an
H.R.S. assessment and the patient completed the Taylor
manifest anxiety scale (T.A.S.).23 At each hourly session the
psychiatrist asked the patient to perform the 100 mm.
line test. (In this test a 100 mm. line is drawn on a sheet
of plain paper and one end is identified " As well as I
could be ", the other end " As depressed as I could be ".
The patient marks where she stands at the moment 01
testing. The score, the length in millimetres from the
" 
well " end of the line, is based on the premise that length
is analogous to the severity of the depression. 24, 25) After
each hourly session he immediately dictated the results
of a brief, informal mental-status examination and inven-
tory of side-effects. At the end of the study another psychia-
trist " blindly " assigned numerical values to transcriptions
of the mental-status examinations. His ratings were in-
tended to be analogous to scores from the H.R.s.
Ankle-reflex time 26 was measured at 3 P.M. on injection
days and throughout the study.
A week after the T.R.H. injection, group-A patients re-
peated the same procedure, except that saline solution was
infused in place of T.R.H. The same nurse attended, and
blood was taken again regularly, though not all of it was
assayed for T.S.H.
Group-B patients were treated in an identical manner,
except that saline was injected the first week and T.R.H.
the second. No other medication than T.R.H. was used
during the project. Only one injection of T.R.H. was given
to each patient because we were then uncertain of the safety
of repeated doses. Placebo capsules were given throughout.
Results
Although our number of patients was small, equal
cell size and placebo cross-over provided considerable
statistical power. We subjected the data to analysis
of variance according to Winer’s technique for re-
peated measurements 27 to examine the baseline
inequalities between groups (none was significant),
interaction, and order effects. By far the greatest
differences were caused by treatments-i.e., by the
differential use of T.R.H. and saline solution. To test
these differences we employed Seal’s multivariate
technique using orthogonal vectors. 28 Data from group
A (first injection, T.R.H.) were combined with data
from group B (second injection, T.R.H.). These data
were then compared with the data from the two
groups when saline was administered.
Three different periods after injection were examined
according to two objectives and two subjective
measures of change. To examine for H.R.s. and T.A.S.
changes we used the 3 P.M. scores from the pre-
injection days as baselines (table I). T.R.H. was superior
to saline in five of twelve instances. Saline was never
superior to T.R.H.
While examining table I, one should recall that on
injection days the 100 mm. line test and the mental-
status examination were performed seven times (two
baseline plus five), while the H.R.S. and the T.A.S. were
performed only once. Thus there was agreement be-
tween the objective and subjective scales performed
frequently and agreement between the objective and
subjective scales performed infrequently.
TABLE I-ADVANTAGES OF T.R.H. INJECTION ON VARIOUS MEASURES
OF MENTAL STATE FOR VARIOUS PERIODS AFTER INJECTION
N.s. =Not significant.
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Changes in Hamilton rating scale scores caused by a single
injection of T.R.H. or saline solution.
On the day of T.R.H. injection patients tended to be
unchanged for an hour, to improve strikingly late in
the morning, and then to relapse toward baseline
toward mid-afternoon. After saline solution, patients
tended to express somatic complaints, often related
to enforced immobility in bed. After arising at noon
they improved somewhat, this being determined
probably in part by diurnal variation in the depression
process.
Although the beneficial effects of T.R.H. seemed by
some measures to dissipate quickly, according to
other measures they persisted. The figure shows the
results of the H.R.S. over the course of the study.
An H.R.S. item analysis indicated that psychic symp-
toms improved more than somatic ones.
Despite slow injection two patients reported a mild
sensation of warmth within 30 minutes of the T.R.H.
injection, one after saline injection. Obviously this
side-effect was too unreliable to have identified the
medication used. No other side-effects and no evi-
dence of toxicity were found.
The physiological and chemical findings seem as
important as the clinical ones. Table m shows that
after the injection of T.R.H. serum-T.S.H. rose. The
patients, however, fell into two distinct groups.
In eight, T.S.H. responses were in the normal range but
at its extreme lower limit. 29, 30 Two, starting from
undectable baseline levels, demonstrated even smaller
increments. In this small series of patients no regular
relationship was apparent between previous psycho-
tropic drug experience and T.S.H. response.
Before and after T.R.H. and saline injections, we
obtained blood for assay of T4 iodine and T3 resin
uptake. The product of each pair of determinations
can be called the thyroxine index as it is proportional
to free thyroxine as determined by other means. 3 i
Table n shows that our patients were euthyroid by this
criteria but tended toward the hypothyroid side of
average. T.R.H. injection caused no more increment in
the thyroxine index than did saline (saline data not
shown).
After completion of the clinical work, serum-total-
T3 analysis became available to us. From five patients
we had deep-frozen sufficient serum to provide
useful information. T.R.H. had no effect on serum-T3
(table 11).
Neither on injection days nor at other times did
T.R.H. or saline affect ankle-reflex time.
Thus four lines of evidence lead to the conclusion
that depressed women experience less of a thyroid-
hormone increment after 600 &micro;g. T.R.H. than normal
men do after 100 g.
Possible relationships between clinical and chemical
changes were a focus of interest. For each patient we
determined the peak T.S.H. rise and the maximum
decrement on the 100 mm. line test during the 6
hours after T.R.H. injection. These measures showed
significant correlation (P<0-01, Spearman rank order).
The relationship between T.s.H. response to T.R.H. and
clinical response to saline (on another occasion) was
random.
Discussion
We must attempt to account for two main findings-
the poor T.s.H. response of our patients to T.R.H. and
the apparent antidepressant effect of T.R.H. injections.
The most obvious explanation for a diminished
T.S.H. response to administered T.R.H. is primary
hyperthyroidism. An excess of circulating thyroid
hormones exerts an increased negative feedback on
pituitary T.S.H. synthesis 33 and less of this substance
is available for release by T.R.H. However, we had
plenty of evidence that our patients were euthyroid and
no evidence whatever that they were hyperthyroid.
T.s.H. response may have been blunted by previous
psychotropic drug experience. However, group-B
patients, who were drug-free 7 days longer than group-
A patients and a total of at least 14 days, showed no
greater response.
Deficient T.s.H. response could occur on another
basis, from deficient endogenous tonic T.R.H. stimu-
lation. This has been shown in animals.34 Although
our findings offer no direct evidence for hypothalamic
underactivity in depression, such evidence exists.
During depression patients are more resistant to the
hypoglycsemic effects of insulin than after recovery. 35.3S B
Furthermore, Sachar et al. 3 have shown that depressed
patients have a diminished growth-hormone output
in response to hypoglycxmia.
TABLE II-EFFECTS OF T.R.H. INJECTION ON T.S.H., THYROXINE INDEX, AND SERUM-T3 (MEANS ibS.E.M.)
I I Minutes after iniection:
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If the hypothalamus is underactive in depression,
how does a hypothalamic hormone exert an anti-
depressant action ? A correlation between anti-
depressant effect and T.s.H. response suggests that the
antidepressant effect is mediated by thyroid hormones.
The concept is plausible, for T3 alone seems to have
antidepressant value. 38 However, T3 must be given in
large doses that speed ankle-reflex time and border
on frank toxicity; and our patients showed no incre-
ment in thyroid state, chemical or physiological.
In any case, the antidepressant effect of T.R.H. need not
be thyroid mediated, since Plotnikoff et al. 1.5 have shown
that T.R.H. will potentiate the behaviour effects of
dopa equally in intact mice and hypophysectomised
mice.
Conceivably, T.R.H. may bypass the pituitary and
exert a direct effect on the thyroid gland, but there is
no evidence to suggest this. T.S.H. will potentiate the
action of imipramine, and it is possible that endogenous
T.S.H., when released after T.R.H. administration, may
exert an antidepressant effect. This seems unlikely,
the more so because large doses of bovine T.S.H.
(given with imipramine) do not cause an antidepressant
effect as rapid as the one seen in our trial.12,13 Our
patients almost certainly experienced a prolactin
release after T.R.H., though this was not measured.
We do not know if prolactin has an antidepressant
effect or not.
We suggest that T.R.H. has a direct central effect.
Consistent with this view is the fact that small amounts
of radioactive T.R.H. appear in the hypothalamus of
rats after intravenous injection. 39 The dopa-poten-
tiating effects of T.R.H. and its antidepressant effect are
consistent with the catecholamine hypothesis of affec-
tive disorders 40-42 in its generic sense, though
Plotnikoff’s data may direct attention to dopamine
rather than to noradrenaline. Dose-response studies
will be needed to clarify the meaning of the correlation
of T.s.H. response and antidepressant response. Con-
ceivably, a " high " (i.e., nearly normal) T.s.H. response
indicates that a fixed dose of T.R.H. has increased likeli-
hood of restoring the hypothalamus to normal levels
of function.
Can T.R.H. be used repeatedly to induce lasting
remission in depression ? Oral T.R.H. may prove useful.
The work of Staub et a!. 4 suggests that the hormone
given by mouth has a prolonged action. We are also
interested in the possibility of T.R.H. being useful in
Parkinson’s disease. L-dopa (levodopa) is useful
in this condition, and T.R.H. potentiates the central
effects of L-dopa in mice. According to our
findings, in man T.R.H. has an effect, probably central,
that is compatible with L-dopa potentiation.
Papavasiliou et a!. 44 have lately reported the calming
and mood-enhancing action of the pineal hormone
melatonin in patients with Parkinson’s disease. They
suggested trials of this substance in mania and de-
pression. It seems possible that brain hormones may
in future play a prominent role in the control of
behavioural disorders.
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Addendum
Similar results to ours have lately been obtained by
Dr. T. M. Itil (personal communication) and by
Dr. A. J. Kastin and his colleagues (Lancet, Oct. 7,
1972, p. 740).
